5 GLP-1 Agonists: Wonder Drugs of the 21st Century
6 Phase III: efficacy and safety of oral semaglutide in T2D 6.1 Overview of the PIONEER program (PIONEER 18) The efficacy and safety of oral semaglutide have been extensively evaluated across the continuum of T2D in the phase III PIONEER clinical trial program [39, 61, 62, 76,77,78,79,80,81,82]
Deeper Dive Before we get into the nuts and bolts I want to discuss a section they called evidence before this study (as always, Ill indent the study content so that you can skip it if youd like and still get the point of the piece.) Although we did not conduct a systematic literature search before doing this study, evidence shows that semaglutide 2-4 mg is effective for weight management
After that, follow-up consults are required every 6 months, or every 9 months for patients on stable maintenance doses